EUCROF Welcomes Four New Members to its Executive Board
Sofia, Bulgaria, 5 June 2026 – During the EUCROF General Assembly held in Sofia, Bulgaria, members elected four new professionals to join the EUCROF Executive Board, further strengthening the federation’s expertise, diversity of perspectives, and commitment to advancing clinical research across Europe.
The newly elected Board members bring extensive experience spanning clinical operations, policy advocacy, patient engagement, digital innovation, and CRO leadership. Together, they represent a shared commitment to strengthening Europe’s position as a leading environment for clinical research and ensuring that the voice of European CROs continues to be heard at both national and European levels.
Doris Neuhauser (Austria)
Country Manager, PSI CRO Austria
With more than 25 years of experience in the pharmaceutical and clinical research industry, Doris Neuhauser brings deep expertise from both sponsor and CRO environments. As Chair of the EUCROF IMPACT Working Group, she has already played a leading role in strengthening EUCROF’s engagement with European stakeholders and policy initiatives, including the EU Biotech Act and ACT EU.
Known for her pragmatic leadership style and focus on delivering tangible outcomes, Doris is passionate about translating dialogue into action and ensuring that EUCROF creates practical value for its members.
“My objective is to ensure that EUCROF delivers not only discussion platforms, but also concrete outputs, access, and influence that all members can actively use, both at European and national level.”
Evangelia (Lia) Koraki (Greece)
President, HACRO | President & CEO, CORONIS Research SA
With more than three decades of experience across pharmaceutical companies, regulatory affairs, and clinical research, Lia Koraki has been a driving force behind the transformation of Greece’s clinical research environment.
As President of HACRO, she has successfully positioned the association as an influential stakeholder in national clinical research policy, contributing to major reforms, strengthening collaboration with healthcare institutions and patient organisations, and helping align national initiatives with European priorities.
Her experience in advocacy, stakeholder engagement, and policy implementation will bring valuable perspective to the EUCROF Executive Board.
“Europe’s clinical research competitiveness is not a given. It must be actively built and defended. The Biotech Act is a critical opportunity, and EUCROF has an essential role to play in ensuring its successful implementation.”
Jean-Sébastien Gosuin (Belgium)
Founder & CEO, CureWiki | Board Member, BeCRO
Entrepreneur, innovator, and advocate for patient-centred healthcare, Jean-Sébastien Gosuin brings a unique perspective to the EUCROF Executive Board. As Founder and CEO of CureWiki, he is helping bridge the gap between patients, healthcare providers, and research through data-driven and AI-enabled solutions.
His international business background, combined with his passion for patient engagement and ecosystem collaboration, strengthens EUCROF’s connection to the broader healthcare community and reinforces the growing importance of patient-centric approaches in clinical research.
“I strongly believe that patient-centered innovation and international collaboration are key to strengthening Europe’s clinical research ecosystem and creating meaningful impact for all stakeholders.”
Dr. Philip Räth (Germany)
Managing Director, Palleos Healthcare GmbH
Dr. Philip Räth brings more than 15 years of experience in clinical research, CRO operations, technology, and business leadership. As Managing Director of Palleos Healthcare, he has worked across finance, business development, data management, eClinical systems, safety, and clinical operations, giving him a broad perspective on the challenges and opportunities facing European research.
A strong advocate for innovation, Philip has also led the implementation of artificial intelligence initiatives and compliance frameworks within his organisation. He joins the Board with a focus on reducing complexity, improving competitiveness, and preparing the sector for the future.
“Clinical trials must remain competitively viable in Europe. This requires clearer communication, reduced complexity, and a stronger, more unified voice for the European CRO community.”
EUCROF’s Next Phase of Growth
The election of these four professionals reflects EUCROF’s continued evolution as the leading voice of European CROs. Their combined expertise in operations, policy, innovation, patient engagement, and stakeholder collaboration will support the federation’s mission and vision to promote high-quality clinical research, foster innovation, and strengthen Europe’s competitiveness in the global clinical research landscape.
The EUCROF Executive Board looks forward to working with its new members as the organisation continues to expand its impact, strengthen partnerships, and contribute to shaping the future of clinical research in Europe.
